Health Catalyst Statistics
Total Valuation
HCAT has a market cap or net worth of $327.95 million. The enterprise value is $259.29 million.
| Market Cap | 327.95M |
| Enterprise Value | 259.29M |
Important Dates
The next confirmed earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCAT has 58.56 million shares outstanding. The number of shares has increased by 4.32% in one year.
| Shares Outstanding | 58.56M |
| Shares Change (YoY) | +4.32% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 89.04% |
| Float | 52.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.58 |
| PS Ratio | 1.11 |
| Forward PS | 1.04 |
| PB Ratio | 0.89 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.42, with a Debt / Equity ratio of 0.68.
| Current Ratio | 4.42 |
| Quick Ratio | 4.25 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 13.94 |
Financial Efficiency
Return on equity (ROE) is -30.60% and return on invested capital (ROIC) is -20.60%.
| Return on Equity (ROE) | -30.60% |
| Return on Assets (ROA) | -16.40% |
| Return on Capital (ROIC) | -20.60% |
| Revenue Per Employee | $227,645 |
| Profits Per Employee | -$90,882 |
| Employee Count | 1,300 |
| Asset Turnover | 0.41 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HCAT has paid $356,000 in taxes.
| Income Tax | 356,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.14% in the last 52 weeks. The beta is 1.29, so HCAT's price volatility has been higher than the market average.
| Beta (1Y) | 1.29 |
| 52-Week Price Change | -54.14% |
| 50-Day Moving Average | 7.51 |
| 200-Day Moving Average | 9.35 |
| Relative Strength Index (RSI) | 32.63 |
| Average Volume (30 Days) | 611,856 |
Short Selling Information
The latest short interest is 1.76 million, so 3.00% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short Previous Month | 1.52M |
| Short % of Shares Out | 3.00% |
| Short % of Float | 3.35% |
| Short Ratio (days to cover) | 2.95 |
Income Statement
In the last 12 months, HCAT had revenue of $295.94 million and -$118.15 million in losses. Loss per share was -$2.09.
| Revenue | 295.94M |
| Gross Profit | 131.83M |
| Operating Income | -126.90M |
| Pretax Income | -117.79M |
| Net Income | -118.15M |
| EBITDA | -81.68M |
| EBIT | -126.90M |
| Loss Per Share | -$2.09 |
Balance Sheet
The company has $317.73 million in cash and $249.07 million in debt, giving a net cash position of $68.66 million or $1.17 per share.
| Cash & Cash Equivalents | 317.73M |
| Total Debt | 249.07M |
| Net Cash | 68.66M |
| Net Cash Per Share | $1.17 |
| Equity / Book Value | 366.92M |
| Book Value Per Share | 6.27 |
| Working Capital | 304.36M |
Cash Flow
In the last 12 months, operating cash flow was -$33.08 million and capital expenditures -$13.16 million, giving a free cash flow of -$46.24 million.
| Operating Cash Flow | -33.08M |
| Capital Expenditures | -13.16M |
| Free Cash Flow | -46.24M |
| FCF Per Share | -$0.82 |
Margins
Gross margin is 44.55%, with operating and profit margins of -42.88% and -39.92%.
| Gross Margin | 44.55% |
| Operating Margin | -42.88% |
| Pretax Margin | -39.80% |
| Profit Margin | -39.92% |
| EBITDA Margin | -27.60% |
| EBIT Margin | -42.88% |
| FCF Margin | -15.63% |
Dividends & Yields
HCAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.32% |
| Shareholder Yield | -4.32% |
| Earnings Yield | -36.03% |
| FCF Yield | -14.10% |
Analyst Forecast
The average price target for HCAT is $12.56, which is 124.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.56 |
| Price Target Difference | 124.29% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HCAT has an Altman Z-Score of -1.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.3 |
| Piotroski F-Score | 2 |